
Caroline Pabst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2258609/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. Blood Advances, 2022, 6, 509-514.	2.5	4
2	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. Vaccines, 2022, 10, 330.	2.1	9
3	CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. EMBO Molecular Medicine, 2022, 14, e14990.	3.3	14
4	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia, 2021, 35, 701-711.	3.3	56
5	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nature Communications, 2021, 12, 1366.	5.8	69
6	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nature Cancer, 2021, 2, 527-544.	5.7	37
7	RSPO2 inhibits BMP signaling to promote self-renewal in acute myeloid leukemia. Cell Reports, 2021, 36, 109559.	2.9	10
8	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. Blood, 2021, 138, 4418-4418.	0.6	3
9	Cooperating mutations: joint forces, novel vulnerabilities. Blood, 2020, 135, 785-787.	0.6	2
10	Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. Blood, 2020, 135, 2059-2070.	0.6	52
11	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia, 2019, 33, 2830-2841.	3.3	30
12	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. Blood, 2019, 134, 263-276.	0.6	41
13	Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia, 2018, 32, 1349-1357.	3.3	31
14	MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia. Blood, 2018, 132, 2627-2627.	0.6	3
15	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nature Medicine, 2017, 23, 69-78.	15.2	192
16	AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nature Cell Biology, 2017, 19, 844-855.	4.6	132
17	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2126.	5.8	91
18	Adhesion GPCRs in Regulating Immune Responses and Inflammation. Advances in Immunology, 2017, 136, 163-201.	1.1	59

CAROLINE PABST

#	Article	IF	CITATIONS
19	GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood, 2016, 127, 2018-2027.	0.6	148
20	Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. Blood, 2016, 127, 3054-3061.	0.6	70
21	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	7.7	341
22	Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia. Blood, 2015, 126, 3855-3855.	0.6	2
23	The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia. Blood, 2015, 126, 1859-1859.	0.6	0
24	Identification of small molecules that support human leukemia stem cell activity ex vivo. Nature Methods, 2014, 11, 436-442.	9.0	115
25	Novel Targeting Strategies for Leukemia-Initiating Cells in Myeloid Neoplasms. Blood, 2013, 122, SCI-27-SCI-27.	0.6	0
26	A High-Throughput Screen to Identify Compounds Preserving Primary Human AML Stem Cells Ex-Vivo,. Blood, 2011, 118, 3587-3587.	0.6	0